18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

IntroductionEarly stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR.Me...

Full description

Bibliographic Details
Main Authors: Bingbing Wen, Yuming Zhang, Haiqing Lin, Jin Lou, Chuangqing Tu, Yirong Jiang, Xiaolian Liu, Yan Chen, Huiqing He, Zelin Liu, Xiaoling Xie, Wangxiang Huang, Liping Pang, Xin Du
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Medicine
Subjects:
18 months
deep molecular response
nilotinib
newly diagnosed
chronic-phase chronic myeloid leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1267512/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1267512/full

Similar Items